Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice

Circulation Research

Volumn 114, Issue 9, 2014, Pages 1435-1445

  Zavadzkas, Juozas A ^a   Stroud, Robert E ^a   Bouges, Shenikqua ^a   Mukherjee, Rupak ^a   Jones, Jeffrey R ^a   Patel, Risha K ^a   McDermott, Paul J ^a,b   Spinale, Francis G ^c,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Ralph H Johnson Veteran's Administration Medical Center   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Extracellular matrix; myocardial infarction; tissue inhibitor of metalloproteinases; ventricular function

Indexed keywords

ADENOVIRUS VECTOR; FIBRILLAR COLLAGEN; GREEN FLUORESCENT PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ECHOCARDIOGRAPHY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EXTRACELLULAR MATRIX; MYOCARDIAL INFARCTION; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR FUNCTION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CYTOKINES; DISEASE MODELS, ANIMAL; FIBRILLAR COLLAGENS; GENE EXPRESSION REGULATION; GENE TARGETING; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; RECOMBINANT FUSION PROTEINS; RECOVERY OF FUNCTION; RNA, MESSENGER; STROKE VOLUME; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84899927847     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.303634     Document Type: Article

References (29)

1. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest. 2005;115:599-609.
2. Ikonomidis JS, Hendrick JW, Parkhurst AM, Herron AR, Escobar PG, Dowdy KB, Stroud RE, Hapke E, Zile MR, Spinale FG. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol. 2005;288:H149-H158.
3. Spinale FG, Escobar GP, Hendrick JW, Clark LL, Camens SS, Mingoia JP, Squires CG, Stroud RE, Ikonomidis JS. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival. J Pharmacol Exp Ther. 2006;318:966-973.
4. Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res. 2006;69:604-613.
5. Yarbrough WM, Mukherjee R, Escobar GP, Mingoia JT, Sample JA, Hendrick JW, Dowdy KB, McLean JE, Lowry AS, O'Neill TP, Spinale FG. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation. 2003;108:1753-1759.
6. Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P, Lyon R, Quinones M, Theroux P, Sydlowski D, Kim HE, Garcia MJ, Jaber WA, Weaver WD. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006;48:15-20.
7. Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res. 2004;10:1963-1970.
8. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects. Expert Opin Ther Targets. 2003;7:385-397.
9. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20:161-168.
10. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006;25:99-113.
11. Kassiri Z, Oudit GY, Sanchez O, Dawood F, Mohammed FF, Nuttall RK, Edwards DR, Liu PP, Backx PH, Khokha R. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res. 2005;97:380-390.
12. Koskivirta I, Kassiri Z, Rahkonen O, Kiviranta R, Oudit GY, McKee TD, Kytö V, Saraste A, Jokinen E, Liu PP, Vuorio E, Khokha R. Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J Biol Chem. 2010;285:24487-24493.
13. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol. 2005;288:H461-H468.
14. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem. 1996;271:30375-30380.
15. Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, Clark LL, Stroud RE, Corn WC, Finklea L, Zile MR, Spinale FG. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation. 2006;114:1020-1027.
16. Wilson EM, Moainie SL, Baskin JM, Lowry AS, Deschamps AM, Mukherjee R, Guy TS, St John-Sutton MG, Gorman JH 3rd, Edmunds LH Jr., Gorman RC, Spinale FG. Region-and type-specific induction of matrix metalloproteinases occurs with post-myocardial infarction remodeling. Circulation. 2003;107:2857-2863.
17. Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, Lowry AS, Escobar GP, Lucas DG, Yarbrough WM, Zile MR, Spinale FG. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107:618-625.
18. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803:55-71.
19. Melendez-Zajgla J, Del Pozo L, Ceballos G, Maldonado V. Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer. 2008;7:85.
20. Zile MR, Baicu CF, Stroud RE, Van Laer AO, Jones JA, Patel R, Mukherjee R, Spinale FG. Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail. 2014;7:340-350.
21. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998;95:2509-2514.
22. Gerald RD, Meidell RS. Adenovirus vectors. In: Hames BD, Glover D, eds. DNA Cloning-A Practical Approach: Mammalian Systems. Oxford, United Kingdom: Oxford University Press; 1995:285-307.
23. Zile MR, Baicu CF, Stroud RE, Van Laer A, Arroyo J, Mukherjee R, Jones JA, Spinale FG. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012;302:H1429-H1437.
24. Lindsey ML, Goshorn DK, Squires CE, Escobar GP, Hendrick JW, Mingoia JT, Sweterlitsch SE, Spinale FG. Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res. 2005;66:410-419.
25. Guo YH, Gao W, Li Q, Li PF, Yao PY, Chen K. Tissue inhibitor of metalloproteinases-4 suppresses vascular smooth muscle cell migration and induces cell apoptosis. Life Sci. 2004;75:2483-2493.
26. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562-573.
27. Zavadzkas JA, Mukherjee R, Rivers WT, Patel RK, Meyer EC, Black LE, McKinney RA, Oelsen JM, Stroud RE, Spinale FG. Direct regulation of membrane type 1 matrix metalloproteinase following myocardial infarction causes changes in survival, cardiac function, and remodeling. Am J Physiol Heart Circ Physiol. 2011;301:H1656-H1666.
28. Goldsmith EC, Bradshaw AD, Spinale FG. Contributory pathways leading to myocardial fibrosis - moving beyond collagen expression. Am J Physiol Cell Physiol. 2013;304:C393-C402.
29. Biernacka A, Dobaczewski M, Frangogiannis NG. TGF- signaling in fibrosis. Growth Factors. 2011;29:196-202.